ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Construction of fibromodulin and borneol-clacked phosphorus dendrimer nanoparticles to reduce inflammation and oxidative stress in BBB to nursing care and ischemic stroke therapy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formulation of novel multi-target combination therapies to address ischemic stroke (ICS) continues to pose significant challenges. This work presents a proof-of-concept display of a proficient nanomedicine formulation consisting of macrophage membrane (MM)-camouflaged phosphorous dendrimer (designated as PD)/fibromodulin (FB) nanoparticles (NPs) clacked with the antioxidant borneol (BN) to regulate both microglia and neurons for efficient ICS therapy. The developed MM@PD-FB/BN NPs, averaging 260 nm in size, exhibit excellent colloidal stability, prolonged BN release kinetics, and favorable cytocompatibility. Due to MM decoration, the MM@PD-FB/BN NPs can traverse the blood-brain barrier, influence microglia to produce anti-inflammatory (PD and FB) and antioxidative (FB and BN) effects in vitro, facilitating oxidative stress mitigation, microglia M2 polarization, and decreased proinflammatory cytokine secretion, while also acting on neuronal cells to exhibit anti-apoptotic properties. In a middle cerebral artery occlusion (MCAO) model, engineered MM@PD-FB/BN NPs demonstrate improved antioxidant, anti-inflammatory, and anti-apoptotic therapeutic effects, modulating the brain microenvironment to restore blood flow. The engineered MM-coated NPs, comprising active components of phosphorous dendrimers, FB, and BN, capable of comprehensively modulating the brain's inflammatory milieu, may broaden the treatment and nursing care of ischemic stroke.
Indexed as
Identifiers
40411619What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.